Amgen Inc
USUSDAmgen Inc (XETRA:AMG) — Biotechnology: Biological Products (No Diagnostic Substances). Biržų, kuriose prekiaujama bendrovės akcijomis, skaičius: 4. Šiame puslapyje — kaina ir grafikas, dividendai, didžiausi akcininkai ir akcijų skaičiaus istorija.
Apie įmonę
- Svetainė
- amgen.com
- Investuotojams
- investors.amgen.com/
- Sektorius
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Būstinė
- Thousand Oaks, United States
- Generalinis direktorius
- Robert A. Bradway
- Darbuotojai
- 17 900
- Įkurta
- 1980
- Biržoje nuo
- 17.11.1998 (XETRA:AMG)
- Apyvartoje esančios akcijos
- 540.63 mln. 2026-07-30 duomenimis
- Laisvai apyvartinės akcijos
- 539.16 mln.
- Rinkos kapitalizacija
- 226.05 mlrd. USD
- Insaideriai
- 0.23%
- Instituciniai investuotojai
- 85.02%
- Šaka (SIC)
- Biological Products, (No Diagnostic Substances)
- Teisinė forma
- XTIQ
- ISIN
- US0311621009
- LEI
- 62QBXGPJ34PQ72Z12S66
- Išmokų santykis
- 60.4%
- FCF
- 10.2 mlrd. USD52%
- Skola
- 57.3 mlrd. USD4.3 m. FCF
- Dividendų stažas
- 15 m.
- Pelnas, FCF ir dividendai – už 12 mėnesių iki 30.06.2026 (naujausia įmonės ataskaita).
Aprašymas
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Biržos ir tikeriai
| Birža | Tikeris | Valiuta | Kaina | Tipas |
|---|---|---|---|---|
| US USA Stocks | AMGN pagrindinis | USD | 407.44 -1.37% | paprastosios akcijos |
| HK Hong Kong Stock Exchange | 4332 papildomas | HKD | — | |
| LSE London Stock Exchange | 0R0T IOB | USD | 411.854 +1.17% | paprastosios akcijos |
| MX Mexican Stock Exchange | AMGN papildomas | MXN | 7 500.0098 +0.00% | paprastosios akcijos |
| XETRA Xetra | AMG papildomas | EUR | 367.95 -1.39% | paprastosios akcijos |
Dividendai
Amgen Inc (AMGN) moka dividendus kas ketvirtį. Per year (12 months up to and including the latest announced payment): 9.94 USD per share (payments: 4). Tai sudaro apie 2.44% dabartinės akcijų kainos. Pagal išmokų istoriją kita ex-dividendų data tikėtina apie 20.11.2026. Nepertraukiamų dividendų metai: 15.
| Ex data | Išmoka | Suma | % | Tipas | Tikeris |
|---|---|---|---|---|---|
| 2026-08-21 | 2026-09-11 | 2.5200 USD | 0.6/2.4 % | kas ketvirtį | US:AMGN |
| 2026-05-15 | 2026-06-05 | 2.5200 USD | 0.6/2.4 % | kas ketvirtį | US:AMGN |
| 2026-02-13 | 2026-03-06 | 2.5200 USD | 0.6/2.4 % | kas ketvirtį | US:AMGN |
| 2025-11-21 | 2025-12-12 | 2.3800 USD | 0.6/2.3 % | kas ketvirtį | US:AMGN |
| 2025-08-22 | 2025-09-12 | 2.3800 USD | 0.6/2.3 % | kas ketvirtį | US:AMGN |
| 2025-05-16 | 2025-06-06 | 2.3800 USD | 0.6/2.3 % | kas ketvirtį | US:AMGN |
| 2025-02-14 | 2025-03-07 | 2.3800 USD | 0.6/≈2.3 % | kas ketvirtį | US:AMGN |
| 2024-11-18 | 2024-12-09 | 2.2500 USD | 0.6/≈2.2 % | kas ketvirtį | US:AMGN |
| 2024-08-16 | 2024-09-06 | 2.2500 USD | 0.6/≈2.2 % | kas ketvirtį | US:AMGN |
Didžiausi akcininkai
| Turėtojas | Dalis | Akcijos | Ataskaitos data |
|---|---|---|---|
| Blackrock Inc. | 9.13% | 49.36 mln. | 2026-06-30 |
| Vanguard Capital Managem… | 6.52% | 35.25 mln. | 2026-06-30 |
| State Street Corporation | 5.65% | 30.56 mln. | 2026-06-30 |
| Capital World Investors | 5.38% | 29.08 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 17.13 mln. | 2026-06-30 |
| Invesco Ltd. | 3.02% | 16.32 mln. | 2026-06-30 |
| Geode Capital Management… | 2.9% | 15.7 mln. | 2026-06-30 |
| Charles Schwab Investmen… | 2.78% | 15.03 mln. | 2026-06-30 |
| Vanguard Portfolio Manag… | 2.75% | 14.85 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 13.99 mln. | 2026-06-30 |
| Morgan Stanley | 2.53% | 13.65 mln. | 2026-06-30 |
| Invesco QQQ Trust, Serie… | 2.15% | 11.61 mln. | 2026-08-31 |
| SCHWAB STRATEGIC TRUST-S… | 1.81% | 9.79 mln. | 2026-05-31 |
| Income Fund of America | 1.44% | 7.76 mln. | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 7.28 mln. | 2026-07-31 |
| Wells Fargo & Company | 1.34% | 7.24 mln. | 2026-06-30 |
| AMERICAN BALANCED FUND | 1.31% | 7.09 mln. | 2026-06-30 |
| Fidelity Concord Street… | 1.29% | 6.98 mln. | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 6.6 mln. | 2026-08-31 |
| WASHINGTON MUTUAL INVEST… | 1.16% | 6.27 mln. | 2026-06-30 |
| BRADWAY ROBERT A (Chief… | ≈0.12% | 657 299 | 2026-05-05 |
| SANTOS ESTEBAN (Officer) | ≈0.02% | 84 279 | 2026-05-05 |
| GORDON MURDO (Officer) | ≈0.01% | 51 837 | 2026-05-05 |
| GRIFFITH PETER H. (Chief… | ≈0.01% | 50 706 | 2026-05-05 |
| REESE DAVID M. (Chief Te… | ≈0.01% | 42 812 | 2026-05-05 |
| GRAHAM JONATHAN P (Gener… | ≈0.01% | 40 211 | 2026-05-05 |
| BRADNER JAMES E. (Office… | ≈0.01% | 30 462 | 2026-05-05 |
| ECKERT ROBERT ANDREW (Di… | ≈0% | 26 251 | 2026-05-19 |
| JACKS TYLER (Director) | ≈0% | 18 284 | 2026-05-19 |
| KULLMAN ELLEN JAMISON (D… | ≈0% | 14 536 | 2026-05-19 |
